Abstract Objective To investigate the incidence, clinical features, and treatment of perinatal cytomegalovirus(CMV) infection, as well as the factors affecting the therapeutic effect of ganciclovir.Methods The clinical data of 237 infants who were hospitalized and diagnosed with perinatal CMV infection from 2008 to 2012 were retrospectively analyzed.Results The clinical features of infants with perinatal CMV infection and the proportion of such infants in all hospitalized infants showed no significant differences across the five years.In most infants, two or more systems were involved, and CMV hepatitis plus CMV pneumonia was most common(43.1%).The results of pathogen detection showed that the percentage of the infants with positive blood CMV-IgM and blood/urine CMV-DNA was 3.8%, while 90.3% of all infants had positive blood CMV-IgM alone and 5.9% had positive blood/urine CMV-DNA alone.A total of 197 infants were treated with ganciclovir, and the cure rate was 88.3%.An abnormal history of pregnancy(OR=6.191, 95% CI:1.597-24.002) and liver involvement before medication(OR=3.705, 95% CI:1.537-8.931) were the independent risk factors affecting the therapeutic effect of ganciclovir in infants with perinatal CMV infection.Conclusions The epidemiological characteristics of perinatal CMV infection have remained generally stable for the last 5 years.CMV often involves several organs or systems, especially the liver and lung.Ganciclovir has a significant efficacy in the treatment of perinatal CMV infection, and an abnormal history of pregnancy and liver involvement before medication can increase the risk of ganciclovir resistance in infants with perinatal CMV infection.
LIU Li-Wei,QIAN Ji-Hong,ZHU Tian-Wen et al. A 5-year retrospective clinical study of perinatal cytomegalovirus infection[J]. CJCP, 2016, 18(2): 99-104.
LIU Li-Wei,QIAN Ji-Hong,ZHU Tian-Wen et al. A 5-year retrospective clinical study of perinatal cytomegalovirus infection[J]. CJCP, 2016, 18(2): 99-104.
Swanson EC, Schleiss MR. Congenital cytomegalovirus infection:new prospects for prevention and therapy[J]. Pediatr Clin North Am, 2013, 60(2):335-349.
[8]
Ivanov IS, Popov NI, Moshe RI, et al. Prevalence of cytomegalovirus infection in hospitalized infants[J]. Folia Med(Plovdiv), 2012, 54(4):45-52.
[9]
Narvaez-Arzate RV, Olguin-Mexquitic L, Lima-Rogel V, et al. Cytomegalovirus infection in infants admitted to a neonatal intensive care unit[J]. J Matern Fetal Neonatal Med, 2013, 26(11):1103-1106.
[10]
Naing Z, Rayner B, Killikulangara A, et al. Prevalence of viruses in stool of premature neonates at a neonatal intensive care unit[J]. J Paediatr Child Health, 2013, 49(3):E221-E226.
[11]
Pereira L, Petitt M, Fong A, et al. Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection[J]. J Infect Dis, 2014, 209(10):1573-1584.
[12]
Hasosah MY, Kutbi SY, Al-Amri AW, et al. Perinatal cytomegalovirus hepatitis in Saudi infants:a case series[J]. Saudi J Gastroenterol, 2012, 18(3):208-213.
[13]
Cybulska P, Ni A, Jimenez-Rivera C. Viral hepatitis:retrospective review in a canadian pediatric hospital[J]. ISRN Pediatr, 2011, 2011:Article ID 182964, 4 pages.
[14]
Bale JF Jr. Fetal infection and brain development[J]. Clin Perinatol, 2009, 36(3):639-653.
[15]
Suzuki Y, Toribe Y, Mogami Y, et al. Epilepsy in patients with congenital cytomegalovirus infection[J]. Brain Dev, 2008, 30(6):420-424.
[16]
White AL, Hedlund GL, Bale JF Jr. Congenital cytomegalovirus infection and brain clefting[J]. Pediatr Neurol, 2014, 50(3):218-223.
[17]
Waters A, Jennings K, Fitzpatrick E, et al. Incidence of congenital cytomegalovirus infection in Ireland:implication for screening and diagnosis[J]. J Clin Virol, 2014, 59(3):156-160.
[18]
Lazzarotto T, Guerra B, Lanari M, et al. New advances in the diagnosis of congenital cytomegalovirus infection[J]. J Clin Virol, 2008, 41(3):192-197.
Choi KY, Sharon B, Balfour HH Jr, et al. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus(CMV) infection[J]. J Clin Virol, 2013, 57(4):356-360.
[23]
Fischer L, Laib Sampaio K, Jahn G, et al. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation[J]. Antiviral Res, 2013, 100(3):575-577.
